<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603616</url>
  </required_header>
  <id_info>
    <org_study_id>32871</org_study_id>
    <secondary_id>32871</secondary_id>
    <nct_id>NCT00603616</nct_id>
  </id_info>
  <brief_title>Induction of Clinical Response Using Rifaximin in Crohn's Disease</brief_title>
  <official_title>A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scott Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotics have been used to treat Crohn's disease symptoms with the best studied&#xD;
      antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is&#xD;
      FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is&#xD;
      very poorly absorbed and over 97% of the drug taken orally is excreted in the feces.&#xD;
&#xD;
      The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for&#xD;
      the treatment of moderate to severe symptoms of Crohn's Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory bowel disease (IBD) is a debilitating chronic inflammatory disease&#xD;
      conventionally categorized into Crohn's disease (CD) and Ulcerative Colitis (UC). CD affects&#xD;
      nearly 630,000 people in North America with up to 50,000 new people being diagnosed every&#xD;
      year. It is a chronic debilitating disease characterized by abdominal pain, malnutrition,&#xD;
      bloody diarrhea, fistula formation, intestinal perforations and strictures, and even&#xD;
      extra-intestinal manifestations such as joint pains and skin rashes. Nearly 80% of people&#xD;
      with CD will need surgical treatment at some point in their disease process. The majority of&#xD;
      CD subjects are diagnosed in young adulthood thereby subjecting them to many decades of&#xD;
      discomfort and medical intervention.&#xD;
&#xD;
      Antibiotics have been used to treat CD with variable response rates. The basis for antibiotic&#xD;
      therapy is that breakdown of the integrity of the mucosal barrier in the gastrointestinal&#xD;
      (GI) tract leads to a heightened inflammatory response to commensurate luminal bacteria. By&#xD;
      changing the composition or bacterial load in the intestinal lumen, it may be possible to&#xD;
      alter the immune response. Ciprofloxacin (Cipro) and metronidazole (Flagyl) are the best&#xD;
      studied antibiotics that have shown efficacy, but the effect is temporal and long term use&#xD;
      can lead to serious side effects. Rifaximin is a recent FDA approved antibiotic with broad&#xD;
      spectrum of activity, excellent safety profile, and minimal absorption from the GI tract.&#xD;
      Open label and small studies in IBD subjects show response rates up to 80% in CD subjects.&#xD;
      These studies were limited however in that they were not randomized placebo controlled&#xD;
      trials.&#xD;
&#xD;
      The investigators propose to conduct a randomized placebo controlled crossover trial of&#xD;
      rifaximin in CD subjects to assess initial clinical response compared to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 3, 2020</completion_date>
  <primary_completion_date type="Actual">November 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of rifaximin 550 mg bid compared to placebo in achieving clinical response in moderate to severe Crohn's Disease (CD) subjects as determined by a &gt; 100 point decrease in the Crohn's Disease Activity Index (CDAI)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of rifaximin compared to placebo at inducing clinical remission in CD subjects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety profile of rifaximin in subjects with active CD</measure>
    <time_frame>16 weeks for those subjects who do not cross over, 32 weeks for those who do cross over</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect rifaximin has on the quality of life in subjects with CD compared to placebo</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate if there are any clinical parameters which might predict response to rifaximin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare mean changes in CDAI scores between rifaximin and placebo treated subjects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifaximin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Matching oral placebo pills to be taken twice daily for a total of 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Xifaxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, 18 to 80 years of age, inclusive, that can themselves provide&#xD;
             written, informed consent and authorization of use of protected health information&#xD;
             prior to any study-related procedures and who are, in the opinion of the&#xD;
             investigator(s), likely to comply with all the requirements of the study&#xD;
&#xD;
          -  Subjects must have a prior diagnosis of CD established by endoscopy and clinical&#xD;
             parameters as determined by the investigator(s) for at least 3 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Subjects must be able to participate in all required follow-up visits and fill out all&#xD;
             related documentation (e.g. symptom diary)&#xD;
&#xD;
          -  Subjects currently with moderately active disease defined as a CDAI 250-450&#xD;
&#xD;
          -  Concomitant medications:&#xD;
&#xD;
               -  If subjects are taking sulfasalazine or 5-ASA products prior to entry, the dose&#xD;
                  must be stable for at least 4 weeks prior to the randomization&#xD;
&#xD;
               -  If subjects are on azathioprine, 6-mercaptopurine, or methotrexate, they will&#xD;
                  have had to be on a stable dosage for at least 8 weeks&#xD;
&#xD;
               -  Subjects are allowed to be on corticosteroids at a dose equivalent to 20 mg or&#xD;
                  less of prednisone, IF the dose has been stable for a minimum of 2 weeks.&#xD;
                  Steroids must be held stable throughout the induction portion of the study. The&#xD;
                  maximum dose of budesonide must not exceed 9mg per day and must also have been&#xD;
                  stable for a minimum of 2 weeks.&#xD;
&#xD;
               -  No oral or intravenous antibiotics within 4 weeks prior to randomization&#xD;
&#xD;
               -  No current or past use of biological treatment within 6 weeks of randomization&#xD;
                  into study (e.g. infliximab)&#xD;
&#xD;
               -  If subjects have previously been on any of the above products but are no longer&#xD;
                  taking them, they should not have received any of the relevant therapeutic&#xD;
                  products within 4 weeks prior to randomization&#xD;
&#xD;
               -  No other experimental or non-FDA approved medications are allowed. If the subject&#xD;
                  has previously been on an experimental therapy, they must have not received the&#xD;
                  therapy within the prior 8 weeks prior to randomization&#xD;
&#xD;
               -  Subjects on concomitant medications for CD will not be allowed to change dosages&#xD;
                  during the study&#xD;
&#xD;
          -  If subjects are at increased risk of colorectal cancer (defined as having an 8-year&#xD;
             history of pan-colitis or 12 year history of left sided colitis), they will need to&#xD;
             have undergone a colonoscopy with pan-colonic surveillance biopsies within 2 years of&#xD;
             the screening visit. The biopsies must be negative for dysplasia&#xD;
&#xD;
          -  Female or male subjects who are surgically sterilized or who are prepared to and agree&#xD;
             to practice a double-barrier form of birth control from the screening visit through 30&#xD;
             days (females) and 30 days (males), respectively, from the last dose of study&#xD;
             medication. Females who are more than 12 months post-menopausal are also eligible to&#xD;
             participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of active infection which may include any of the following&#xD;
&#xD;
               -  Febrile ( &gt; 38.5ÂºC)&#xD;
&#xD;
               -  Positive blood culture within 2 weeks prior to randomization&#xD;
&#xD;
               -  Evidence of toxic megacolon or abscess&#xD;
&#xD;
               -  Positive stool culture for enteric pathogens, pathogenic ova or parasite, or a&#xD;
                  positive assay for C. difficile toxin at screening&#xD;
&#xD;
          -  Subjects with CDAI &gt; 450&#xD;
&#xD;
          -  Any current use or use within the last 8 weeks of an investigational drug&#xD;
&#xD;
          -  Current or past use (within past 12 wks) of biological treatment&#xD;
&#xD;
          -  Current or use within the last 4 weeks of any oral or intravenous antibiotic&#xD;
&#xD;
          -  Anticipated increased dosage of any medication to treat CD&#xD;
&#xD;
          -  Anticipated need for surgery within 12 weeks&#xD;
&#xD;
          -  Known obstructive diseases of the gastrointestinal system&#xD;
&#xD;
          -  Medical conditions requiring in-patient hospitalization&#xD;
&#xD;
          -  Proctocolectomy, total colectomy, ileostomy, or stoma&#xD;
&#xD;
          -  Severe cardiopulmonary disease:&#xD;
&#xD;
               -  Congestive heart failure (NYHA Class III or IV)&#xD;
&#xD;
               -  Severe cardiovascular or peripheral vascular disease&#xD;
&#xD;
               -  Myocardial infarction, percutaneous coronary intervention, or bypass surgery&#xD;
                  within the past 6 months&#xD;
&#xD;
          -  Significant liver disease:&#xD;
&#xD;
               -  Levels of SGOT [AST], SGPT [ALT], or alkaline phosphatase &gt; 2.5x the upper limit&#xD;
                  of the normal range for the laboratory performing test&#xD;
&#xD;
               -  History of cirrhosis&#xD;
&#xD;
          -  Renal insufficiency, defined as serum creatinine &gt; 150% of the upper limit of the&#xD;
             normal range for the laboratory performing the test&#xD;
&#xD;
          -  Abnormal hematology parameters defined as severe anemia with hemoglobin &lt; 8.5 g/dL&#xD;
             and/or white blood cell count of &lt; 3,500/ul&#xD;
&#xD;
          -  Malignancy within the past 2 years other than surgically cured skin carcinoma or&#xD;
             cervical dysplasia (CIN I-II)&#xD;
&#xD;
          -  History of dysplasia or carcinoma of the colon&#xD;
&#xD;
          -  Pregnant, lactating, or planning to become pregnant during the course of the&#xD;
             investigational study&#xD;
&#xD;
          -  Known history of allergic reaction to rifaximin or allergy to any of the rifamycin&#xD;
             antimicrobial agents (which include rifampin, rifabutin, and rifapentine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott D Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Scott Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Crohn disease</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>Rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

